Immune checkpoint blockade (ICB) therapy, using monoclonal antibodies targeting immune-inhibitory receptors like PD-1/PD-L1 and CTLA-4, seeks to reactivate the impaired T-cell response against tumor. This evidence concerns the gene CTLA4 and neoplasm.